Related references
Note: Only part of the references are listed.Aflibercept Treatment for Macular Edema following Branch Retinal Vein Occlusion: Age-Based Responses
Ender Sirakaya et al.
OPHTHALMOLOGICA (2020)
Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion
Glenn Yiu et al.
OPHTHALMOLOGY RETINA (2020)
INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION A Randomized Clinical Trial
Manuel Casselholm de Salles et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2019)
Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors
Maria-Magdalena Guichard et al.
OPHTHALMIC RESEARCH (2018)
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications Secondary Outcomes From the SCORE2 Randomized Clinical Trial
Ingrid U. Scott et al.
JAMA OPHTHALMOLOGY (2018)
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion 52-Week Results of the VIBRANT Study
W. Lloyd Clark et al.
OPHTHALMOLOGY (2016)
Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion Six-Month Results of BRIGHTER
Ramin Tadayoni et al.
OPHTHALMOLOGY (2016)
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion The 24-Week Results of the VIBRANT Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2015)
Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab The RETAIN Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2014)
Monthly Versus As-Needed Ranibizumab Injections in Patients with Retinal Vein Occlusion The SHORE Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2014)
Ranibizumab for Macular Edema Due to Retinal Vein Occlusions Long-term Follow-up in the HORIZON Trial
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion
Gesine B. Jaissle et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2011)
Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study
David M. Brown et al.
OPHTHALMOLOGY (2011)
Retinal vein thrombosis: pathogenesis and management
M. Rehak et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2010)
The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia
Sophie Rogers et al.
OPHTHALMOLOGY (2010)
The 15-year cumulative incidence of retinal vein occlusion - The beaver dam eye study
Ronald Klein et al.
ARCHIVES OF OPHTHALMOLOGY (2008)
Predicted biological activity of intravitreal VEGF trap
M. W. Stewart et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities
Jiri Rehak et al.
CURRENT EYE RESEARCH (2008)
Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion
Eun Jee Chung et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2008)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
